Los Angeles Capital Management LLC Sells 23,715 Shares of Phibro Animal Health Corporation $PAHC

Los Angeles Capital Management LLC lessened its holdings in Phibro Animal Health Corporation (NASDAQ:PAHC) by 38.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,444 shares of the company’s stock after selling 23,715 shares during the period. Los Angeles Capital Management LLC’s holdings in Phibro Animal Health were worth $1,436,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in shares of Phibro Animal Health by 1,730.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after buying an additional 225,110 shares in the last quarter. Millennium Management LLC boosted its stake in Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after buying an additional 154,281 shares in the last quarter. Advisors Preferred LLC acquired a new stake in Phibro Animal Health in the 3rd quarter valued at $3,953,000. Lazard Asset Management LLC grew its position in Phibro Animal Health by 3,392.3% in the second quarter. Lazard Asset Management LLC now owns 92,441 shares of the company’s stock valued at $2,360,000 after acquiring an additional 89,794 shares during the period. Finally, Barclays PLC grew its position in Phibro Animal Health by 47.4% in the third quarter. Barclays PLC now owns 269,568 shares of the company’s stock valued at $10,907,000 after acquiring an additional 86,719 shares during the period. Institutional investors own 99.34% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on PAHC. Wall Street Zen lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Weiss Ratings cut shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 8th. Finally, Citigroup dropped their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $38.80.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 10,560 shares of Phibro Animal Health stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $52.68, for a total transaction of $556,300.80. Following the transaction, the chief executive officer directly owned 80,360 shares of the company’s stock, valued at $4,233,364.80. This trade represents a 11.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 74,928 shares of company stock worth $4,017,273 over the last quarter. Company insiders own 50.13% of the company’s stock.

Phibro Animal Health Price Performance

PAHC opened at $31.18 on Thursday. The company has a fifty day moving average price of $44.83 and a two-hundred day moving average price of $44.93. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17. Phibro Animal Health Corporation has a 52 week low of $23.57 and a 52 week high of $60.08. The firm has a market capitalization of $1.26 billion, a PE ratio of 13.38, a P/E/G ratio of 0.49 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The firm had revenue of $383.54 million during the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, analysts anticipate that Phibro Animal Health Corporation will post 3.07 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be given a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.5%. The ex-dividend date of this dividend is Wednesday, June 3rd. Phibro Animal Health’s dividend payout ratio (DPR) is currently 20.60%.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.